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Abstract 
TNF-stimulated gene-6 (TSG-6) is a 
multifunctional protein secreted in response 
to pro-inflammatory stimuli by a wide range 
of cells including neutrophils, monocytes and 
endothelial cells. It has been shown to mediate 
anti-inflammatory and protective effects 
when administered in disease models, in part, 
by reducing neutrophil infiltration. Human 
TSG-6 inhibits neutrophil migration by 
binding CXCL8 through its Link module 
(Link_TSG6) and interfering with the 
presentation of CXCL8 on cell-surface 
glycosaminoglycans (GAGs), an interaction 
that is vital for the function of many 
chemokines. TSG-6 was also found to interact 
with chemokines CXCL11 and CCL5, 
suggesting the possibility that it may function 
as a broad specificity chemokine-binding 
protein, functionally similar to those encoded 
by viruses. The present study was therefore 
undertaken to explore the ability of TSG-6 to 
regulate the function of other chemokines. 
Herein, we demonstrate that Link_TSG6 
binds chemokines from both the CXC and 
CC families, including CXCL4, CXCL12, 
CCL2, CCL5, CCL7, CCL19, CCL21 and 
CCL27. We also show that the Link_TSG6 
binding sites on chemokines overlap with 
chemokine GAG-binding sites, and that the 
affinity of Link_TSG6 for these chemokines 
(KD values 1-85 nM) broadly correlates with 
chemokine:GAG affinity. Link_TSG6 also 
inhibits chemokine presentation on 
endothelial cells not only through a direct 
interaction with chemokines, but also by 
binding and therefore masking the 
availability of GAGs. Along with previous 
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work, these findings suggest that TSG-6 
functions as a pluripotent regulator of 
chemokines by modulating chemokine:GAG 
interactions, which may be a major 
mechanism by which TSG-6 produces its anti-
inflammatory effects in vivo. 
 
TSG-6 is an inflammation-associated 
protein that has been shown to be up-regulated 
by pro-inflammatory mediators such as IL-1, 
TNF and LPS in a broad range of cells and in the 
context of inflammatory diseases (1-6). It is a 
~35 kDa secreted protein composed of Link and 
CUB_C domains with an additional short N-
terminal sequence (5, 7-10). Although initially 
found at high levels in the joints of patients with 
rheumatoid and osteoarthritis, suggesting a pro-
inflammatory role (1), administration of TSG-6 
was found to inhibit damage in inflammatory 
models including arthritis (11-14) and transplant 
rejection (15), suggesting it possesses anti-
inflammatory properties. TSG-6 has also been 
identified as a key mediator of anti-
inflammatory effects of human mesenchymal 
stem cells in models of myocardial infarction 
(4), corneal damage (16), peritonitis (17), 
traumatic brain injury, (18) acute lung injury 
(19), wound healing (20) and type 1 diabetes 
(21). One mechanism underlying its protective 
effects is thought to be its ability to inhibit the 
influx of neutrophils to inflammatory sites and 
the concomitant neutrophil-induced damage (4, 
16, 18, 22, 23). To understand the basis for the 
protective effect of TSG-6, the Link module 
(Link_TSG6) was expressed in isolation (24, 25) 
and shown to reproduce the effects of the full-
length protein in inhibiting neutrophil migration 
(26) and in binding to a number of ligands 
including the glycosaminoglycans (GAGs), 
heparin and heparan sulfate (HS) (27, 28); 
moreover, Link_TSG6 inhibited rolling and 
transendothelial migration of neutrophils as 
determined by intravital microscopy (29). 
Link_TSG6 was also shown to interact with 
CXCL8 and to inhibit its presentation on and 
transport across endothelial cells, as well as its 
ability to recruit neutrophils (30), providing at 
least a partial explanation for the anti-
inflammatory effects of TSG-6.  
CXCL8 is a member of the chemotactic 
cytokine (chemokine) family of proteins, which 
are best known for their roles in regulating cell 
migration.  They mediate cell recruitment by 
signaling through chemokine receptors on 
leukocyte cell surfaces (31-34). However, in 
addition to activating these G protein-coupled 
signaling receptors on migrating cells, 
chemokines interact with cell surface GAGs (35-
40). GAGs/proteoglycans are found in the 
extracellular matrix (ECM) (41) and 
ubiquitously on essentially all cell surfaces 
including endothelial cells where they comprise 
a key component of the glycocalyx (41-44). The 
interaction of chemokines with GAGs enables 
their cell surface localization and facilitates 
formation of chemotactic gradients in order to 
guide leukocytes to sites of infection and 
inflammation (40). Moreover, GAG-binding has 
been shown to be integral to the function of a 
number of chemokines including CXCL8 (38, 
39), CXCL12 (37), CCL2 (35), CCL5 (35), 
CCL7 (36) and CCL21 (40).  
Given the prior observation that TSG-6 
inhibits binding of CXCL8 to heparin and 
endothelial cell surfaces resulting in down-
regulation of CXCL8-mediated neutrophil 
migration (30), we hypothesized that TSG-6 
might inhibit GAG-mediated cell surface 
presentation of other chemokines that recruit 
different cell types (45). This hypothesis was 
motivated by the fact that in addition to 
neutrophils, TSG-6 administration results in 
reduced infiltration of other cell types during 
inflammation including monocytes (46), T cells 
and dendritic cells (47).  
In this study, we demonstrate the ability 
of Link_TSG6 to interact with a wide range of 
chemokines from the CC and CXC subfamilies. 
Furthermore, we show that Link_TSG6 interacts 
with the GAG-binding region of these 
chemokines and inhibits their presentation on 
endothelial surfaces. These TSG-6:chemokine 
interactions are of particular interest given the 
lack of soluble chemokine binding proteins 
identified in humans and other vertebrates, 
despite many having been identified in ticks, 
parasites and viruses (48-50). Moreover, while 
chemokines play an integral role in the 
regulation of inflammation, their pharmaceutical 
targeting has proved largely unsuccessful and 
such binding proteins could have therapeutic 
potential (51, 52). 
 
Experimental Procedures 
 
Protein production and purification 
WT Link_TSG6 and the mutant 
Link_TSG6_T (K55A/K69A/K76A) (numbered 
as in the pre-protein here and throughout the rest 
of the manuscript (7) were expressed in E. coli 
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and refolded/purified as described previously 
(24, 25, 27). Biotinylated and WT chemokines 
CXCL4, CXCL12, CCL2, CCL5, CCL7, 
CCL19, CCL21 and CCL27 and associated 
mutants, where CCL21 ΔCT relates to residues 
1-79 as described previously (53), were 
expressed and purified from E. coli as described 
in (54-56).  
 
Surface plasmon resonance (SPR) 
In all instances, a Biacore 3000 
instrument (GE Healthcare) was used to generate 
binding curves. Analyte was flowed over the 
chip surface in running buffer (10 mM HEPES, 
150 mM NaCl, 0.05% Tween-20 (v/v), pH 7.4) 
at varying concentrations for 5 minutes at 40 
µl/min; subsequently, running buffer alone was 
flowed over the bound ligand and a non-specific 
control surface for 5 minutes at 40 µl/min to 
monitor the dissociation phase of the interaction. 
Curves were then corrected with subtraction of 
non-specific and buffer alone signals and 
analyzed with the BIAevaluation software (GE 
Healthcare) using the 1:1 Langmuir interaction 
model. The degree of fit to this model was 
assessed by using the Chi2 values, where 
Chi2<10 was accepted as a good fit. In the 
instances where the Chi2 value was significantly 
higher than 10 and visual inspection of the data 
suggested poor fitting, alternative models were 
used to fit the data (bivalent analyte or two-state 
reaction models); however, in no instances did 
these models improve the fit to the raw data. 
Given the less than ideal fitting for some 
datasets involving chemokines with Link_TSG6, 
the calculated affinities are considered “apparent 
affinities”, but they still allow for relative 
ranking of the interactions. These difficulties 
arise from the propensity of certain chemokines 
to oligomerize, as described in (57). 
 
SPR analysis of chemokine binding to 
immobilized Link_TSG6 
The Link_TSG6 surface was generated 
on a C1 chip (GE Healthcare) as described 
previously (30). Briefly, the surface was 
activated with 100 µl of a 1:1 mix of N-
hydroxysuccinimide (NHS; 0.1 M) and 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDC; 
0.2 M) before flowing over Link_TSG6 (20 
µg/ml) in immobilization buffer (10 mM 
HEPES, pH 7.4) at 20 µl/min until the desired 
immobilization level was reached (800-1000 
RU). Remaining active sites on the chip surface 
were blocked with 1 M ethanolamine (120 µl). 
The surface was then washed with 1 M NaCl 
followed by regeneration buffer (50 mM 
NaOH). Results from replicate chemokine 
injections before and after surface regeneration 
and at various times throughout the use of a 
given chip were used to monitor surface 
integrity; the data were highly reproducible 
indicating that the Link_TSG6 surface was 
unaffected by the regeneration treatment and 
remained stable throughout the experiments. 
Interaction analysis was undertaken as described 
above with a number of different chemokines 
and associated mutants; any ligand remaining 
bound to the Link_TSG6 surface was fully 
removed with regeneration buffer (160 µl) prior 
to the analysis of a different ligand.  
 
SPR analysis of Link_TSG6 binding to 
immobilized heparin 
A heparin surface was generated on a 
C1 chip as described previously (56). First, 
neutravidin was covalently immobilized to the 
surface until saturation using the EDC:NHS 
chemistry described above. This surface was 
then washed extensively to remove non-
covalently bound neutravidin before biotinylated 
unfractionated porcine intestinal heparin 
(CalBiochem) (0.2 mg/ml in 100 mM sodium 
acetate, pH 5.5) was flowed over this surface at 
10 µl/min, until saturation was reached. SPR 
analysis was carried out as described above to 
determine the affinity of Link_TSG6 for 
immobilized heparin, using the same approach 
described previously to analyze 
chemokine:heparin interactions (56). 
Regeneration buffer was used following each 
cycle of chemokine injection and interaction 
analysis to clean the chip surface. 
 
Chemokine:heparin interactions in solid-
phase binding assays 
Solid phase binding assays were 
undertaken as described previously (30). Briefly, 
CCL2, CCL7, CCL19, or CXCL11 (250 nM) 
was immobilized onto Nunc MaxiSorp plates 
(ThermoScientific) in coating buffer (20 mM 
Na2CO3, pH 9.6) for 16 hours at room 
temperature. Wells were then rinsed using assay 
buffer (10 mM NaOAc, 150 mM NaCl, 2% (v/v) 
Tween-20, pH 6.0) and blocked with assay 
buffer containing 5% (w/v) BSA at 37˚C for 90 
minutes. Biotinylated heparin (made from 4th 
International Standard, described in (58)) was 
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then added at increasing concentrations (0-100 
ng/well), or for competition binding assays, 
biotinylated heparin (25 ng/well) was added in 
combination with a range of Link_TSG6_T 
concentrations (0-2000 nM) in assay buffer at 
room temperature for 4 hours. Plates were 
washed with assay buffer and the level of bound 
heparin was then assessed by addition of 
Extravidin-alkaline phosphatase (1:10,000) 
(Sigma) and subsequent incubation with 
detection reagent (SigmaFAST p-nitrophenyl 
phosphate solution (Sigma)). After 5 minutes of 
development, absorbance levels (405 nm) were 
taken and signal corrected against blank wells 
(no coated chemokine); in cases where 
differential background of coated/uncoated wells 
led to negative corrected values (i.e. at high 
Link_TSG6_T concentrations) these were 
assigned a value of zero. Data were analyzed 
and fit to the non-linear regression one-site 
binding model (GraphPad Prism Version 5.0, 
Graph Pad Software) to provide an estimate of 
the IC50 values.  
 
Chemotaxis and transendothelial migration 
Chemotaxis experiments were 
undertaken using a 5 µm pore Transwell system 
(Corning) as described previously (56).  Here, 
CCL19 or CCL21 (50 nM) was pre-incubated 
alone or in combination with different molar 
ratios of Link_TSG6 (1:2 or 1:1, 
Link_TSG6:chemokine) for 30 minutes at 
37˚C/5% CO2 in 600 µl of Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% fetal 
bovine serum (FBS) in the bottom chamber of 
the Transwell. L1.2 cells induced to express 
CCR7 or CCR5 (by incubation with 5 mM 
sodium butyrate for 18 hours), or Jurkat cells 
expressing CXCR4, were re-suspended in 
DMEM containing 10% FBS before addition to 
the top chamber of the Transwell apparatus (100 
µl of 2 x 106 cells/ml). Wells were incubated for 
2 hours at 37˚C, 5 % CO2 before the suspended 
membranes were removed and the cells in the 
bottom chamber (migrated cells) counted using a 
Guava EasyCyte 8HT flow cytometer (EMD 
Millipore). For transendothelial migration 
experiments, EaHY926 human umbilical vein 
endothelial cells (HUVECs) (100 µl of 1 x 106 
cells/ml) were coated onto a suspended 
Transwell membrane overnight in DMEM 
containing 10% FBS. The surface of the 
endothelial cells was washed with 100 µl of 
DMEM and aspirated before the experiment was 
undertaken as described above for chemotaxis 
experiments. 
 
Endothelial/collagen chemokine presentation 
assay  
These assays were undertaken using a 
similar method to that described previously (56). 
Specifically, a clear-bottomed black-walled 96-
well polystyrene plate (Corning) was coated 
with 200 µl of 100 µg/ml type I collagen 
(Purecol, Advanced Biomatrix) for 1 hour at 
37˚C. EaHY926 HUVECs were added to each 
well (200 µl of 0.1 x 106 cells/ml (20,000 
cells/well) in DMEM containing 10% FBS) and 
incubated for 18 hours (until confluent); this and 
all subsequent cellular incubations were carried 
out in 5% CO2 at 37˚C. Non-adherent cells were 
removed by washing with DMEM followed by 
two washes with PBS supplemented with 1 mM 
CaCl2 and 0.5 mM MgCl2 (cPBS). Alternatively, 
assays were undertaken on a collagen-coated 
surface alone. Biotinylated chemokine (CXCL4, 
CXCL12 and CCL21) or unlabeled chemokine 
(CCL2, CCL5 and CCL7) was incubated alone 
or in combination with different molar ratios of 
Link_TSG6 or heparin octasaccharide (dp8 
(Neoparin); dp = degree of polymerization) in 
cPBS for 30 minutes at 37˚C before being added 
on top of the washed endothelial monolayer and 
incubated for 1 hour. Alternatively, Link_TSG6 
(500 nM) was pre-incubated on top of the 
washed endothelial cells for 30 minutes followed 
by three washes with cPBS and subsequent 
incubation of chemokine with endothelial cells 
for 1 hour. Chemokine/Link_TSG6 solutions 
were then aspirated and the monolayers washed 
three times with cPBS for 2 minutes, before 
fixation of cells with 150 µl of ice-cold 4% 
(w/v) paraformaldehyde in PBS for 20 minutes 
at room temperature; these and subsequent 
washes/incubation were carried out with gentle 
rocking. The fixative agent was removed and the 
endothelial cells washed (4 incubations of 4 
minutes) using PBS + 0.05% Tween-20 before 
addition of 150 µl of blocking solution (LI-COR 
Biosciences) to each well and incubation for 90 
minutes at room temperature. This solution was 
aspirated and, in the case of biotinylated 
chemokine, detection was undertaken with 100 
µl of blocking solution containing streptavidin 
conjugated to IRDye 800CW biotin detection 
reagent (LI-COR Biosciences; 1:1000), which 
was added to each well and incubated for a 
further 90 minutes at room temperature. For 
 TSG-6 Inhibits Chemokine:Glycosaminoglycan Interactions   5 
non-labeled chemokine detection, 100 µl of 
blocking solution containing antibodies against 
CCL2, CCL5 or CCL7 (R&D systems, 1 µg/ml) 
was added to each well and incubated for 1 hour 
at room temperature. Cells were then washed 4 
times (4 minutes) with 100 µl of PBS + 0.05% 
Tween-20, before addition of anti-goat IgG 
800CW conjugate (1:5000) (LI-COR 
Biosciences) secondary antibody in blocking 
solution for 1 hour at room temperature. In all 
cases this solution was aspirated from the 
endothelial cells, which were then finally 
washed with 100 µl of PBS + 0.05% Tween-20  
(4 incubations of 4 minutes), followed by bound 
chemokine detection using an Odyssey imaging 
system (LI-COR Biosciences). 
 
Cell adhesion assay 
Murine bone marrow derived dendritic cells 
(BMDCs) were cultured in DC media (RPMI, 
10% FBS, 1% Penicillin-Streptomycin, 2 mM L-
glutamine, 10 mM HEPES, 1 mM non-essential 
amino acids, and 55 µM β-Mercaptoethanol) in 
the presence of 20 ng/ml of recombinant murine 
GM-CSF (Peprotech) for ten days.  On day nine, 
BMDCs were treated with 200 ng/ml of 
lipopolysaccharide (LPS 055:B5 (Sigma)) for 24 
hours. One day prior to the assay, murine 
lymphatic endothelial cells (SV-LECs, 
Alexander Lab, LSU Cell Culture Repository, 
LSU) were seeded on to a clear-bottomed, black-
walled 96-well plate (Falcon) at 6.75 x 103 
cells/well. Prior to use, BMDCs were stained 
with Calcein AM (eBioscience) for 1 hour.  
Murine CCL21 (Biolegend) alone or in the 
presence of a 1:1 molar equivalent of 
Link_TSG6 was diluted in serum free DMEM, 
incubated at room temperature for 30 minutes 
and then added to the SV-LECs and incubated  
for an additional 30 minutes at 37˚C/5% CO2.  
Following chemokine incubation on the SV-
LECs, media was removed and 1 x 104 of 
Calcein-labeled BMDCs were added to each 
well. After five minutes, cell fluorescence was 
measured on a plate reader  (DTX880, Beckman 
Coulter) to determine the maximum 
fluorescence for each well. Wells were then 
promptly washed two times with PBS to remove 
unbound BMDCs and read again to determine 
the extent of BMDC adhesion for each 
condition.    
 
 
 
Results 
The TSG-6 Link module binds to 
multiple chemokines 
Having previously established that 
Link_TSG6 inhibits CXCL8-mediated 
transendothelial migration of neutrophils via 
interactions with CXCL8, we set out to 
investigate whether it also interacts with other 
chemokines, explaining its ability to inhibit the 
migration of diverse cell types (46, 47) and to 
produce anti-inflammatory effects (5, 8). For 
these experiments, we used SPR with 
Link_TSG6 immobilized on an SPR chip and 
passed chemokines over the surface at varying 
concentrations. The rates of association (ka) and 
dissociation (kd) were determined from the 
sensorgrams and used to calculate dissociation 
constants (KD = kd/ka) with a 1:1 Langmuir 
interaction model. Interestingly, the SPR data 
revealed that Link_TSG6 binds to ten different 
chemokines (Table 1, Figure 1) including 
CXCL4, CXCL11, CXCL12, CCL2, CCL7, 
CCL19, CCL21 and CCL27 (in addition to the 
known interactions with CXCL8 and CCL5 
(30)) with KD values ranging from 1 to 85 nM. 
The chemokines fall into three major groups 
where CXCL4 (3.9 nM), CXCL11 (5.2 nM), 
CCL5 (1.9 nM) and CCL21 (4.8 nM) comprise a 
high affinity group (1-5 nM), CXCL8 (21 nM) 
(30), CXCL12 (15 nM), CCL2 (29.4 nM), CCL7 
(18.4 nM) and CCL19 (17.5 nM) have slightly 
lower affinities (15-30 nM), and CCL27 showed 
the weakest interaction (85.2 nM). A fourth 
category is also apparent as Link_TSG6 has 
previously been shown to have little, if any, 
affinity for CXCL1 or CCL3 (30). 
 
The GAG-binding sites of all 
chemokines tested are important for interactions 
with TSG-6 
Previous studies revealed that the GAG-
binding region of CXCL8 is involved in its 
interaction with Link_TSG6 (30), leading us to 
hypothesize that GAG-binding domains of the 
chemokines identified above will also be 
important for Link_TSG6-chemokine complex 
formation.  To this end, we tested whether well-
characterized GAG-binding deficient chemokine 
mutants, known to have significantly impaired 
interactions with heparin or HS, also show a 
reduced affinity for Link_TSG6. As 
demonstrated by the sensorgrams in Figure 2 
and the calculated affinities in Table 1, this 
turned out to be the case. Binding to Link_TSG6 
was effectively abolished for the R18A/K19A 
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mutant of CCL2 (59), the R44A/K45A/R47A 
mutant of CCL5 (60) and a C-terminal deletion 
mutant of CCL21 (53). While interaction with 
Link_TSG6 could be detected with the CCL7 
mutant K18A/K19A/K22A (GAG-binding null 
(56)), there was insufficient signal to calculate a 
reliable dissociation constant, indicative of a 
weak interaction. The CXCL12 GAG-binding 
deficient mutant K24S/H25S/K27S (61) could 
still bind Link_TSG6 suggesting additional 
epitopes contribute to the interaction; 
nevertheless, the affinity was ~55-fold lower 
than WT CXCL12. Similarly, the CCL27 K25A 
mutant displayed an ~9-fold reduction in affinity 
for Link_TSG6, and the retention of residual 
binding is unsurprising as a single point 
mutation would not be expected to completely 
eliminate GAG or protein binding. Finally, we 
could detect only a weak interaction between 
Link_TSG6 and CCL3 (15 mM (30)), similar to 
the weak-to-no interaction reported for this 
chemokine with GAGs (57, 62).  Recently we 
published apparent affinities determined by SPR 
for the interaction of HS with CXCL4, CXCL8, 
CXCL11, CXCL12, CCL2, CCL5, CCL7 (56, 
57) and CCL27. A plot of these apparent 
affinities against Link_TSG6:chemokine 
affinities demonstrates that there is a positive 
correlation (Figure 3). Taken together these data 
suggest that the chemokine binding sites for 
Link_TSG6 and GAGs overlap, similar to the 
situation with CXCL8 (30). 
 
TSG-6 blocks chemokine:GAG 
interactions but not chemokine:receptor 
interactions 
The overlap between the Link_TSG6 and GAG-
binding sites on chemokines suggests that a 
contributing mechanism by which TSG-6 exerts 
its anti-inflammatory function in vivo may be by 
blocking chemokine:GAG interactions, which 
are known to be critical for chemokine function 
(35-40). To test this hypothesis, an ELISA-based 
solid phase binding assay was devised. 
Specifically, CCL2 and CXCL11, 
(representatives of CC and CXC chemokines, 
respectively) were separately immobilized onto 
MaxiSorp plates and incubated with increasing 
concentrations of heparin, resulting in a 
saturating interaction between the chemokine 
and GAG (Figure 4A). These assays were then 
repeated with immobilized chemokine 
(CXCL11, CCL2, CCL7 or CCL19) in the 
presence of a fixed, saturating concentration of 
heparin in combination with increasing 
concentrations of the Link_TSG6_T 
(K55A/K69A/K76A) mutant (Figure 4B and 
C); this mutant was chosen because it has 
greatly reduced ability to bind heparin (27) and 
thereby simplifies the interpretation of the 
resulting data. In line with the above hypothesis, 
the Link_TSG6 mutant resulted in a dose 
dependent inhibition of the binding of all the 
chemokines tested to heparin with IC50 values 
estimated to be 168 nM (CXCL11), 84 nM 
(CCL2), 159 nM (CCL7) and 55 nM (CCL19).  
To investigate whether Link_TSG6 
inhibits the interaction of chemokines with 
receptor in addition to interactions with GAGs, 
we conducted bare filter chemotaxis assays in 
which chemokine was placed in the bottom well 
of a Transwell apparatus and L1.2 cells, 
transfected with appropriate receptor, were 
placed in the top well. Similar to a previous 
study where Link_TSG6 had no effect on the 
migration of CXCR1-expressing cells (30), 
Link_TSG6 did not affect the migration of 
CCR5- or CCR7- bearing L1.2 cells towards 
CCL5, CCL19 or CCL21 or of Jurkat cells that 
endogenously express CXCR4, towards 
CXCL12 in the bare filter assay (Figure 5). 
These data suggest that although Link_TSG6 
directly binds these chemokines, it does not 
block their interaction with their respective 
receptors.  
 
Link_TSG6 inhibits chemokine 
presentation on endothelial cells and collagen, 
and subsequent chemokine-mediated cell 
adhesion 
The finding that Link_TSG6 interacts 
with the GAG-binding region of chemokines led 
us to test whether Link_TSG6 could affect 
chemokine binding and presentation on 
endothelial cells, a process known to be 
mediated by cell surface GAGs (63, 64). Pre-
incubation of Link_TSG6 with six different 
chemokines resulted in reduced chemokine 
accumulation on endothelial cells in all cases 
except CCL5 (Figure 6). The potency of its 
inhibitory trend was chemokine specific as a 1:1 
Link_TSG6:chemokine molar ratio was 
sufficient to significantly reduce the endothelial 
cell accumulation of CCL7 (down to 50% of the 
level of chemokine alone), CCL21 (50% of 
chemokine alone), and CCL2 (~75% and ~55% 
of chemokine alone at a 1:1 and 5:1 ratio, 
respectively, Figure 6A-C). However, CXCL12 
and CXCL4 required a 5-fold molar excess of 
Link_TSG6 to reduce accumulation to 68% and 
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51%, of chemokine alone, respectively (Figure 
6D and E, respectively); lower ratios of 
Link_TSG6:CXCL4 had no effect on endothelial 
binding of the chemokine (data not shown). No 
inhibition of CCL5 was observed at a 5:1 ratio 
of Link_TSG6 to chemokine (Figure 6F). 
Importantly, when the experiment was 
performed using heparin dp8 instead of 
Link_TSG6 in the same molar excess that 
caused reduced chemokine binding with 
Link_TSG6, a similar inhibition of chemokine 
accumulation on the endothelial cells was 
observed for CCL7, CCL21, CCL2 and CXCL4 
(Figure 6A, B, C and E, respectively). In the 
case of CXCL12, pre-incubation with either 
heparin dp8 or Link_TSG6 had similar 
inhibitory effects on chemokine accumulation 
although in contrast to Link_TSG6, the effect of 
heparin did not reach significance (Figure 6D).  
Link_TSG6, was previously 
demonstrated to have a moderate affinity (~3 
µM) interaction with dp8 heparin by isothermal 
titration calorimetry (27). By comparison and as 
shown by the SPR data in Figure 7, Link_TSG6 
binds unfractionated heparin (average molecular 
mass = 15 kDa, dp 10-80) with higher affinity 
(~22 nM); this is not surprising since larger 
GAGs have been observed to have higher 
affinity for chemokines (62). This affinity is in 
the range of chemokine:heparin interactions 
(57), and prompted us to investigate whether 
Link_TSG6 could also affect 
chemokine:endothelial cell surface binding when 
incubated with the cells prior to introduction of 
chemokine. This experimental design 
specifically addresses an alternative mechanism 
of inhibition, where Link_TSG6 binds 
endothelial GAGs, and thereby affects 
subsequent chemokine:GAG interactions. In this 
experiment, Link_TSG6 inhibited the 
accumulation of CXCL4 (33% inhibition), 
CXCL12 (36% inhibition), CCL2 (42 % 
inhibition), CCL7 (32% inhibition), CCL21 
(17% inhibition) and CCL5 (45% inhibition) on 
endothelial cell surfaces (Figure 8). These data 
suggest that Link_TSG6 can prevent endothelial 
presentation via a direct interaction with 
chemokines and also by masking or limiting 
available cell surface GAGs.  
Chemokines are found abundantly in the 
ECM (31), and TSG-6 is known to function in 
the ECM (5, 9, 10). Thus, following our 
observations that Link_TSG6 can inhibit 
chemokine presentation on endothelial cells, we 
investigated whether it inhibits chemokine 
binding to collagen, an important component of 
the ECM. In agreement with previous studies 
describing chemokine:collagen interactions (65, 
66), we observed that CCL21, CXCL12 and 
CXCL4 bind to collagen-coated surfaces 
(Figure 9A). Notably, pre-incubation of these 
chemokines with Link_TSG6 resulted in dose 
dependent inhibition of their binding to collagen 
(Figure 9B, C and D). These findings suggest 
TSG-6 may function as a general modulator of 
chemokine presentation on endothelial cell HS 
and extracellular matrix components including 
GAGs and collagen.  
Link_TSG6 did not inhibit the 
interaction of chemokines studied herein with 
their receptors as shown by its inability to affect 
cell migration in an in vitro bare filter 
chemotaxis assay.  However, since Link_TSG6 
inhibits presentation on endothelial GAGs, we 
questioned whether it would inhibit 
transendothelial cell migration, a process that 
requires transport of chemokine across the 
endothelial layer and can involve GAG-
dependent transcytosis (30, 64, 67). Moreover, 
in a previous study, Link_TSG6 significantly 
inhibited transendothelial migration of cells 
towards CXCL8, which correlated with impaired 
CXCL8 transcytosis and impaired presentation 
of the chemokine on the apical surface (30). In 
the present study, it inhibited CCL19- and 
CCL21-mediated transmigration of L1.2/CCR7 
cells, albeit modestly, at both 1:2 (~22% and 
~19% inhibition, respectively) and 1:1 (~26% 
and ~18% inhibition, respectively) 
Link_TSG6:chemokine ratios (Figure 10). As 
transcytosis has been suggested to account for 
only 10% of chemokine transport, with 
pericellular transport by diffusion of chemokine 
through gaps between endothelial cells 
accounting for ~90% (64), it is not surprising 
that only modest inhibition was observed. 
Additionally, we did not observe any inhibitory 
effects on CXCL12 or CCL5-mediated 
transmigration of receptor-bearing Jurkat or L1.2 
cells, respectively (Figure 10C and D), which 
suggests that these chemokines are transported 
predominantly by a pericellular route. Although 
only modest inhibition of CCL21-mediated 
transendothelial cell migration was observed, we 
sought to determine whether Link_TSG6 could 
disrupt other steps in this process. Specifically, 
inhibition of dendritic cell adhesion to the 
endothelium was tested, given the established 
reduction in CCL21 accumulation on the apical 
surface of endothelial cells in the presence of 
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Link_TSG6 (Figure 6B). Pre-incubation of 
CCL21 with Link_TSG6 at a 1:1 molar ratio 
significantly reduced CCL21-mediated BMDC 
adhesion to close to control levels (with a mean 
value of 40% inhibition and a range of 23-71% 
inhibition across replicate experiments) (Figure 
10E). This finding provides additional evidence 
for a biologically relevant consequence of TSG-
6-mediated regulation of chemokine function.  
 
Discussion 
The TSG-6 Link module mediates 
binding to multiple chemokines 
Given that Link_TSG6 inhibits 
neutrophil recruitment and associated 
inflammation by blocking the function of 
CXCL8, we set out to test whether it inhibits the 
function of other chemokines. These studies 
were also motivated by its broad anti-
inflammatory effects in several disease models 
where a wide range of other chemokines and cell 
types play a role (4, 11-19, 22, 23). Indeed, we 
demonstrated that Link_TSG6 binds to multiple 
chemokines from both the CC and CXC 
families, including CXCL4, CXCL11, CXCL12, 
CCL2, CCL5, CCL7, CCL19, CCL21 and 
CCL27. This group not only includes 
chemokines from two of the four chemokine 
subfamilies but also those classified as 
inflammatory (CXCL4, CXCL11, CXCL12, 
CCL2, CCL5 and CCL7) versus homeostatic 
(CCL19 and CCL21) (68, 69).   
The fact that TSG-6 binds to most 
chemokines tested raises the question as to the 
likelihood that it would be present in the same 
location as these chemokines in vivo. TSG-6 
expression during inflammation is well 
established (5, 8), and it is known to be secreted 
by inflammatory cells such as peripheral blood 
mononuclear cells (1, 7, 70), neutrophils (71), 
mast cells (72) and macrophages (71, 73) in 
response to signals including LPS and TNF (1, 
7, 70, 71). TSG-6 is also produced by stromal 
cells such as fibroblasts (7, 74) and human 
umbilical vein endothelial cells (71). Likewise, 
many chemokines are associated with 
inflammation (34, 75) and expressed by a similar 
range of inflammatory (45, 76-78) and 
endothelial (79, 80) cells. Unlike inflammatory 
chemokines, CCL19 and CCL21 are associated 
with lymphatic trafficking of dendritic cells via 
CCR7 (81); thus their expression is more limited 
to cells in lymphatic vessels. Nevertheless, the 
fact that monocyte derived dendritic cells 
produce TSG-6 in response to LPS (71), 
suggests that lymphatic dendritic cells could also 
produce TSG-6. Similarly, human umbilical vein 
and microvascular endothelial cells have been 
shown to produce TSG-6 (71, 82), and TSG-6 
has been implicated in the function of 
hyaluronan (HA) binding to the LYVE-1 
receptor on lymph vessel endothelial cells (83). 
Overall, it seems likely that TSG-6 and 
chemokines would be co-expressed in vivo at 
sites of inflammation and in the lymphatic 
system.  
 
TSG-6 interacts with chemokines 
through their GAG-binding sites and inhibits 
their binding to GAGs and endothelial cell 
surfaces 
In prior studies of CXCL8 (30), it was 
shown that Link_TSG6 does not exert its 
inhibitory effects by disrupting 
chemokine:receptor interactions (except at high 
micromolar concentrations in the case of 
CXCR2). Instead it primarily blocks the 
interaction of CXCL8 with GAGs (27), which 
indirectly affects cell migration (35-40). 
Chemokine:GAG interactions are thought to be 
required for the formation of chemokine 
gradients on cell surfaces and in the ECM, as 
demonstrated for CCL21 in the context of 
dendritic cell recruitment (40). Moreover, GAG-
binding deficient mutants of CXCL8, CXCL12, 
CCL2, CCL5 and CCL7 all show a significantly 
impaired ability to recruit cells in vivo, despite 
their capacity to promote cell migration in bare 
filter chemotaxis assays where GAG binding is 
not required (35-37, 39). Given the prior data on 
CXCL8, we hypothesized that TSG-6 would 
also target the GAG-binding sites of the 
chemokines identified as ligands in this study. 
Indeed, we showed that mutation of GAG-
binding residues in chemokines greatly reduced 
the affinity of Link_TSG6. Thus it was not 
surprising to find that incubation of Link_TSG6 
with most of the tested WT chemokines 
inhibited their presentation on endothelial cell 
surfaces (Figure 11A, C). Furthermore, 
Link_TSG6 was as effective as heparin at 
inhibiting endothelial presentation (when used at 
an equivalent molar ratio), and it also blocked 
binding of chemokines to collagen, an important 
component of the ECM.  
The exception to these findings was the 
lack of inhibition of CCL5 binding to 
endothelial cells following pre-incubation with 
Link_TSG6, despite the high affinity interaction 
between the two. The mechanistic reason for the 
 TSG-6 Inhibits Chemokine:Glycosaminoglycan Interactions   9 
anomalous behavior of CCL5 is unknown; 
however, CCL5 is unique in forming large stable 
polymers in solution and it has a very high 
affinity for cell surface GAGs because of avidity 
effects from multiple GAG binding sites on its 
surface (57). While speculative, it may be that 
upon pre-incubation with CCL5, TSG-6 is 
unable to mask all GAG-binding sites on the 
CCL5 polymer and that the remaining GAG 
sites are still permissive to its interaction with 
cell surface GAGs. However, when TSG-6 is 
pre-incubated with the endothelial surface, it 
may be a more effective mechanism for blocking 
the subsequent binding of CCL5 by sterically 
preventing the formation of high affinity 
GAG/CCL5 polymer complexes that would 
normally occur.  Further studies will be required 
to test this possibility. 
In addition to inhibiting the binding of 
chemokines to endothelial cells by interacting 
with the GAG-binding epitopes on chemokines, 
we showed that TSG-6 can directly interact with, 
and thereby mask cell surface GAGs (Figure 
11A, B). In support of these findings, it is well 
established that the Link_TSG6 interacts with a 
wide variety of GAGs including chondroitin 
sulfate (CS), dermatan sulfate, heparin/HS and 
HA (27, 28). Furthermore, in this study we 
demonstrate that Link_TSG6 binds to heparin 
with an affinity (~20 nM) that is similar to its 
affinity for several chemokines (56, 57). We also 
showed that the affinities of chemokines for 
Link_TSG6 strongly correlate with their 
affinities for HS. This ‘matching’ of binding 
strengths would be expected to allow TSG-6 to 
modulate chemokine binding to GAGs in a 
highly concentration-dependent manner.  
The ability of the TSG-6 Link module to 
dimerize when bound to heparin and CS (27, 84) 
may contribute to its potency in sequestering 
chemokine-binding sites on GAGs through an 
avidity effect. Crosslinking of GAGs by TSG-6 
may also affect the accessibility or conformation 
of chemokine-binding sites on GAGs. Binding 
of the CUB_C domain to fibronectin in the 
context of full length TSG-6 (85) may also 
provide additional tethers that further strengthen 
its interactions with GAGs, collagen and/or 
other ECM substrates. Collectively, these 
mechanisms for sequestering chemokine-binding 
sites on endothelial and ECM GAGs may 
contribute to the broad-spectrum activities of 
TSG-6, and presumably affect not only the 
chemokines investigated here, but any 
chemokine whose function is dependent on 
GAG-binding. 
By inhibiting the presentation of 
chemokines on cell surface GAGs and collagen, 
Link_TSG6 is predicted to cause the disruption 
of chemokine gradients, resulting in impaired 
cell migration (40). However, the in vitro 
migration assays used in this study are 
inadequate for testing this hypothesis because, 
apart from a potentially small contribution of 
GAG-mediated transcytosis on cell migration, 
there is little or no dependence of 
transendothelial migration on GAG interactions. 
This is due to the fact that Transwell migration 
assays automatically establish a chemokine 
gradient by the separation of chemokine and 
cells between the two chambers, eliminating the 
need for GAGs. Furthermore, sample 
confinement in the wells and lack of shear 
forces/flow prevent rapid dissipation of 
chemokines that might otherwise happen in vivo 
in the absence of GAG interactions (35).  More 
complex in vitro (under flow) or in vivo assays 
will be required to further probe the mechanistic 
basis for the anti-inflammatory properties of 
TSG-6 with respect to how it affects gradient 
formation of chemokines and subsequently cell 
migration, similar to previous studies with 
GAG-binding deficient chemokines (35-37, 39).  
 
Insights into the recognition between 
chemokines and TSG-6  
In the present study, we showed that 
TSG-6 binds to all chemokines tested through 
their GAG-binding sites. The high resolution 
molecular details of how it does so remains an 
important question since chemokines are overall 
basic proteins, but TSG-6 is basic as well (pI 
~9.48, (84)). Previously it was shown that a 
mutant of Link_TSG6 (Link_TSG6_T), with 
reduced capacity to bind heparin (27), was still 
capable of  binding to CXCL8 and inhibiting  
both its interaction with GAGs and 
transendothelial cell migration towards CXCL8 
(30). Similarly, in this study, we showed that 
this Link_TSG6 mutant could inhibit CXCL11, 
CCL2, CCL7 and CCL19 interactions with 
heparin. These findings suggest that the heparin-
binding site on Link_TSG6 (Figure 12) does not 
overlap its binding site for CXCL8, and the 
above chemokines, which may very well be the 
case for other chemokines. This would not be 
surprising since the heparin-binding surface of 
Link_TSG6 is composed of basic residues, 
making it incompatible with chemokine GAG-
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binding sites, which are also defined by clusters 
of Arg, Lys and His (86, 87). Instead, the 
interaction with the GAG-binding domains of 
chemokines may be mediated by negatively 
charged amino acids in Link_TSG6 (Figure 12). 
Alternatively, as the binding site on Link_TSG6 
for HA/CS is non-overlapping with heparin and 
enriched with aromatic residues, it is possible 
that it could provide a binding site for 
chemokines (Figure 12). In this case, favorable 
cation-π interactions (88, 89) between the 
Link_TSG6 aromatic residues and Lys/Arg 
residues in the chemokine GAG-binding 
epitopes could contribute to complex formation.  
Identification of the chemokine binding sites on 
TSG-6 will be the subject of future studies. 
The present data also suggest that, 
although the binding sites for chemokines and 
heparin on Link_TSG6 do not overlap, it is 
probable that chemokine and heparin (and likely 
HS) do not simultaneously bind the Link module 
(Figure 11). This is because Link_TSG6 blocks 
cell surface presentation of chemokines, whereas 
if GAG and chemokine could both bind to the 
Link module, the opposite effect might be 
expected. This suggests that an allosteric 
mechanism may prevent simultaneous binding 
of GAG and chemokine, as has been suggested 
for the competing interactions of HA and 
heparin for their distinct binding sites on 
Link_TSG6 (27, 84). On the other hand, if 
chemokines bind to the HA/CS binding site of 
TSG-6 (27, 84), then binding of chemokine and 
these GAGs to TSG-6 would simply be 
competitive and mutually exclusive. 
In addition to basic epitopes defining the 
GAG-binding sites of chemokines, many 
chemokines oligomerize by themselves and the 
oligomers are stabilized by GAGs (56, 90-93). 
Furthermore, oligomerization plays a critical 
role in the affinity of chemokines for heparin, 
HS and CS (39, 56, 57, 94).  Whether or not 
chemokine oligomerization affects binding to 
Link_TSG6 is not yet clear and will be also the 
subject of future studies.  
 
TSG-6 is a broad spectrum chemokine 
binding protein 
We previously identified TSG-6 as the 
first known mammalian soluble chemokine-
binding protein (30) and can now further define 
it as a broad spectrum chemokine binding 
protein that interacts with multiple chemokines 
via their GAG-binding domains. Thus, the 
cumulative abilities of TSG-6 to inhibit 
chemokine interactions with GAGs as well as 
collagen, to exert inhibitory effects in the ECM 
and on cell surfaces, and to directly bind 
chemokines and GAGs, together create a robust 
mechanism by which TSG-6 is able to modulate 
the function of many chemokines with 
potentially significant anti-inflammatory 
consequences (11-14, 16-19, 23).  In fact, TSG-6 
may represent a general regulator of heparin/HS-
binding proteins; in addition to ten chemokines, 
TSG-6 interacts with seven heparin/HS-binding 
bone morphogenetic proteins (BMPs) (95), at 
least in part, via its Link module. How a single 
protein can bind so many other proteins is 
reminiscent of viral chemokine binding proteins 
that promote virulence by sequestering 
chemokines and suppressing the immune 
response (96). For example, the chemokine 
binding protein M3, produced by γ-Herpes virus 
68, can bind to both receptor- and GAG-binding 
domains of chemokines (97) thereby inhibiting 
chemokine function by two separate 
mechanisms. E163 from Poxvirus is similar to 
TSG-6 in that it interacts with chemokines 
through their GAG-binding epitopes and also 
binds directly to GAGs, but does not inhibit 
interactions of chemokines with their receptors 
(98). The similarity of TSG-6 with these various 
chemokine-binding proteins underscores its role 
as a pluripotent anti-inflammatory mediator of 
chemokine function. Its ability to interact with 
so many chemokines may add to its known 
functions in the ECM and explain some of its 
protective effects in models of inflammatory 
disease (11-14), and its more recently described 
role in protection against inflammatory damage 
mediated by human mesenchymal stem cells (4, 
16-18, 23).  Inhibition of the presentation of 
chemokines on cell surface and ECM GAGs 
would be expected to impair leukocyte migration 
in vivo due to the lack of an immobilized 
chemokine gradient for the cells to follow (40).  
Thus, TSG-6 expression may provide a novel 
mechanism whereby cellular presentation of 
chemokines can be regulated and finely tuned.   
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Footnotes: 
 
1 Abbreviations used are: TSG-6, TNF-stimulated gene/protein 6; SPR, surface plasmon resonance; 
Link_TSG6, recombinant Link module from human TSG-6; GAG, glycosaminoglycan; CXCL, CXC-
type chemokine ligand; ECM, extracellular matrix; CCL, CC-type chemokine ligand; HS, heparan 
sulfate; CS, chondroitin sulfate; HA, hyaluronan; WT, wild type. 
2 The content is solely the responsibility of the authors and does not necessarily represent the official 
views of the National Institutes of Health. 
  
Figure Legends: 
 
Figure 1. Multiple chemokines bind to immobilized Link_TSG6. Link_TSG6 was immobilized 
onto a Biacore C1 chip and different chemokines were passed over in running buffer at various 
concentrations to generate affinity estimates. Experimental curves are plotted (black lines) with fits 
(red lines) generated from a 1:1 Langmuir interaction model using analytes at a range of 
concentrations to generate “on” (ka) and “off” (kd) rates for the interaction and overall affinity (KD = 
kd/ka)). (A) CXCL4 (400, 200, 100, 50, 40 and 40 nM), (B) CXCL11 (200, 150, 100, 75, 50), (C) 
CXCL12 (400, 200, 100, 50, 40, 40, 25, 12.5 and 6.25 nM), (D) CXCL12 K24S/H25S/K27S (200, 
150, 100, 75, 50, 37.5, 37.5, 25 and 12.5 nM), (E) CCL2 (1000, 750, 500, 400, 250, 250, 200, 100, 50 
nM), (F) CCL7 (1000, 750, 500, 400, 250, 250, 200, 100, 50 and 25 nM), (G) CCL19 (200,150, 100, 
75, 50, 37.5 and 25 nM), (H) CCL21 (200, 150, 100, 75, 50, 37.5, 37.5, 25, 12.5 nM), (I) CCL27 
(1000, 500, 400, 250, 250, 200, 100 and 50 nM) and (J) CCL27 K25A (1000, 750, 500, 400, 250, 
250, 200, 100 and 50 nM).  
 
Figure 2. Chemokines bind Link_TSG6 through their GAG-binding epitopes. Link_TSG6 was 
immobilized onto a C1 chip.  Chemokines and their corresponding GAG-binding mutants were then 
passed over the immobilized Link_TSG6 at 40 µl/min and the resulting interaction monitored. The 
response units (RU) on the y-axis reflect the amount of chemokine bound: (A) CCL2 and 
R18A/K19A (1000 nM), (B) CCL5 and R44A/K45A/R47A (200 nM), (C) CCL21 and C-terminal 
truncated mutant (200 nM), (D) CCL7 and K18A/K19A/K22A (1000 nM), (E) CXCL12 and 
K24S/H25S/K27S (200 nM) and (F) CCL27 and K25A (1000 nM).  
 
Figure 3. Correlation between chemokine affinity for Link_TSG6 and HS. Kinetic affinity 
estimates for each chemokine binding to immobilized HS (56, 57) or Link_TSG6 are plotted, as 
calculated using SPR. Data shown are from individual measurements representative of two 
independent experiments. CXCL8 is excluded from this figure as previous studies did not enable 
evaluation of a robust affinity estimate for the CXCL8:HS interaction (57).  
 
Figure 4. Link_TSG6 inhibits the interaction of chemokines with heparin. (A) Chemokine (250 
nM) was immobilized onto MaxiSorp plates and incubated with increasing amounts of biotinylated 
heparin (0-100 ng/well), plates were then washed and bound heparin detected. (B) CXCL11 or CCL2 
(250 nM) (C) CCL7 or CCL19 (250 nM) were immobilized onto MaxiSorp plates and then incubated 
with a constant amount of biotinylated heparin (25 ng/well) in combination with increasing 
concentrations of the Link_TSG6_T mutant (K55A/K69A/K76A) (0-1000 nM), which has reduced 
heparin-binding activity.  The amount of bound biotinylated heparin was then detected and plotted as 
a percentage of the maximum binding observed in the absence of competitor. Data are plotted as the 
mean of three independent experiments (±SEM), each undertaken in quadruplicate (n = 3) with 
background signal subtracted. 
 
Figure 5. Pre-incubation with Link_TSG6 has no effect upon CCL5, CCL19, CCL21 or 
CXCL12 mediated chemotaxis of CCR7, CCR5 or CXCR4 expressing cells. (A-D) CCL5 (1 nM), 
CCL19 (50 nM), CCL21 (50 nM) or CXCL12 (1 nM) was added to the bottom chamber of a 
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Transwell system with or without pre-incubation with the indicated molar ratio of Link_TSG6 
(Link_TSG6:chemokine). (A) CCR5, (B,C) CCR7 or (D) CXCR4 expressing cells were added to the 
top well on the suspended membrane; following incubation (2 hours, 37˚C) the numbers of migrated 
cells were counted. Data are normalized to the level of migration mediated by chemokine alone, 
plotted as mean values (± SEM) from two independent experiments, each undertaken in duplicate 
(n=2).  
 
Figure 6. Pre-incubation of chemokine with Link_TSG6 inhibits subsequent presentation on the 
endothelial cell surface. (A) CCL7 (50 nM), (B) CCL21 (50 nM), (C), CCL2 (50 nM), (D) CXCL12 
(50 nM), (E) CXCL4 (10 nM) and (F) CCL5 (10 nm) were incubated either alone or in combination 
with different molar ratios of Link_TSG6 or heparin dp8 (ratios given as Link_TSG6:chemokine or 
dp8:chemokine) prior to incubation on the endothelial cell surface, followed by washing and detection 
of bound chemokine. Data are expressed as a percentage of maximal binding of chemokine alone, 
plotted as mean values (± SEM) from three independent experiments, each undertaken in duplicate 
(n=3). *P < 0.05, **P < 0.01, ***P < 0.001 (compared to chemokine-only controls) and ns = no 
significant difference (*P > 0.05) between samples treated with equivalent molar ratios of Link_TSG6 
and dp8, as determined using repeated measures ANOVA analysis with a Bonferroni post hoc test.  
 
Figure 7. Link_TSG6 binds immobilized heparin. Heparin was immobilized onto a C1 Biacore 
chip before Link_TSG6 was passed over in running buffer at a range of concentrations (750, 500, 
400, 250, 200, 100 and 50 nM). Rates of association (ka) and rates of dissociation (kd) were used to 
calculate overall affinity (KD = kd/ka). The quality of the fit to a 1:1 Langmuir model is given by Chi2 
values calculated by application of this model, where Chi2<10 is indicative of a good fit. 
 
Figure 8. Pre-incubation of Link_TSG6 on the endothelial cell surface inhibits subsequent 
chemokine presentation. Endothelial monolayers were incubated with/without Link_TSG6 (500 nM) 
followed by washing and addition of (A) CCL7 (50 nM), (B) CCL21 (50 nM), (C) CCL2 (50 nM), 
(D) CXCL12 (50 nM), (E) CXCL4 (10 nM) and (F) CCL5 (10 nM) to the endothelial cell surface; 
after washing the level of bound chemokine was determined. Data are expressed as a percentage of 
maximal binding of chemokine alone, plotted as mean values (± SEM) from three independent 
experiments, each undertaken in duplicate (n=3). *P < 0.05, **P < 0.01  (compared to chemokine-
only controls), as determined using Student’s t-test. 
 
Figure 9. Pre-incubation of chemokine with Link_TSG6 inhibits subsequent presentation on 
collagen. (A) Biotinylated CCL21, CXCL12 or CXCL4 were incubated at different concentrations 
(10, 50 or 200 nM) on wells pre-coated with collagen and the amounts bound following washing were 
detected using labeled streptavidin. The biotinylated chemokines, (B) CCL21 (50 nM), (C) CXCL12 
(50 nM) or (D) CXCL4 (10 nM), were incubated either alone or in combination with different molar 
ratios of Link_TSG6 (ratios given as Link_TSG6:chemokine) prior to incubation on the collagen 
coated surfaces, followed by detection as before. Data are expressed in (A) as total binding (Relative 
fluorescence intensity) or in (B-D) as a percentage of maximal binding of chemokine alone, plotted as 
mean values (± SEM) from two independent experiments, each undertaken in duplicate (n=2). *P < 
0.05, **P < 0.01 (compared to chemokine-only controls), as determined using repeated measures 
ANOVA analysis with a Bonferroni post hoc test. 
 
Figure 10. Pre-incubation with Link_TSG6 inhibits CCL19 and CCL21, but not CXCL12 or 
CCL5 mediated transenothelial migration of CCR7, CXCR4 or CCR5 expressing cells, and 
CCL21 mediated adhesion of BMDCs. CCL19 (50 nM), CCL21 (50 nM), CXCL12 (1 nM) or 
CCL5 (1 nM) were added to the bottom chamber of a Transwell with or without pre-incubation with 
the indicated molar ratio of Link_TSG6 (Link_TSG6:chemokine), (A and B) CCR7, (C) CXCR4 or 
(D) CCR5 expressing cells were added to the top well in the presence of an endothelial monolayer on 
the suspended membrane; following incubation (2 hours, 37˚C) the numbers of migrated cells were 
counted. Data were normalized to the level of migration mediated by chemokine alone, plotted as 
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mean values (± SEM) from three independent experiments, each undertaken in duplicate (n=3). *P < 
0.05, **P < 0.01 (compared to chemokine-only controls), as determined using repeated measures 
ANOVA analysis with a Bonferroni post hoc test. (E) CCL21 (10 nM), pre-incubated at a 1:1 molar 
ratio with Link_TSG6, was incubated with SV-LECs (30 min, 37˚C) followed by addition of BMDCs. 
BMDC adhesion (percentage of total maximal signal) is plotted as mean values for triplicate wells (± 
SD) from a representative data set of 6 independent experiments.  ***P < 0.001 for CCL21 alone 
compared to vehicle control or for Link_TSG6:chemokine compared to CCL21 alone; ,determined 
using a one-way ANOVA analysis with a Bonferroni post hoc test.  
 
Figure 11. Model of TSG-6 inhibition of chemokine:GAG interactions.  (A) Chemokines (green) 
bind to GAGs (branched structures) present on endothelial cells (shown) and within the ECM (not 
shown) via GAG-binding sites on the chemokine (depicted as dark line).  Integral to their function, 
chemokine:GAG interactions enable the retention and accumulation of chemokines on cell surfaces, 
which leads to the formation of chemokine gradients involved in directing cell migration.  (B, C) In 
inflammatory settings, TSG-6 (purple) is upregulated and inhibits chemokine function by blocking the 
cell surface presentation of chemokines. One mechanism for how TSG-6 can exert its inhibitory 
effects is by directly binding to GAGs on the cell surface, thus limiting available GAG for chemokine 
interactions (B).  Additionally, TSG-6 binds chemokines directly through their GAG-binding 
domains, thereby blocking chemokine interactions with GAG by competing for a common binding 
surface (C).   
 
 
Figure 12. Interaction sites for CS/HA, heparin and potential binding sites for chemokines on 
Link_TSG6.  Structure of a Link_TSG6 complex with CS (PDB code 24N0), where Link_TSG6 is 
shown as a surface mesh and CS is shown as a space-filling model. The green surface of Link_TSG6 
highlights the aromatics that define the CS/HA binding site (9, 84) and could provide a binding site 
for chemokines through their GAG-binding epitopes. The blue surface highlights the basic residues 
that define the heparin-binding site as determined in (99), which is not compatible with chemokine 
binding. The red surface highlights Glu residues that could provide a binding site for chemokines 
through their GAG-binding epitopes.  
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Tables: 
 
Table 1. Surface plasmon resonance analysis of chemokine and mutant affinities for a 
Link_TSG6 coated surface.  
Rates of association (ka) and rates of dissociation (kd) were used to calculate overall affinity (KD = 
kd/ka) values for chemokine binding to immobilized Link_TSG6. The quality of the fit to a 1:1 
Langmuir model is given by Chi2 and the Rmax (RU) values calculated by application of this model, 
where Chi2<10 or Chi2<10% of Rmax is indicative of a good fit. Data are representative of two 
independent experiments. 
Chemokine ka (M-1 s-1) kd (s-1) KD (nM) Chi2 Rmax (RU) 
CXCL4 3.6 x 105 1.4 x 10-3 3.9 52.9 270 
CXCL8a 1.9 x 104 3.9 x 10-4 21 18.1 202 
CXCL11 2.5 x 105 1.3 x 10-3 5.2 27.5 135 
CXCL12 1.4 x 105 2.1 x 10-3 15 18.3 109 
K24S/H25S/K27S  1.2 x 104 1.0 x 10-2 833.3 2.3 108 
CCL2 5.1 x 104 1.5 x 10-3 29.4 5.5 80.3 
R18A/K19A  bNOI NOI NOI NOI NOI 
CCL5a 5.7 x 104 1.1 x 10-4 1.9  7.3 265 
R44A/K45A/R47A  cNPA NPA NPA NPA NPA 
CCL7 8.7 x 104 1.6 x 10-3 18.4 4.1 41.9 
K18A/K19A/K22A NPA NPA NPA NPA NPA 
CCL19 1.6 x 105 2.8 x 10-3 17.5 5.3 53.4 
CCL21 7.1 x 105 3.4 x 10-3 4.8 18.7 99.5 
ΔCT  NPA NPA NPA NPA NPA 
CCL27 2.7 x 104 2.3 x 10-3 85.2 8.8 81.9 
K25A  8.1 x 103 6.1 x 10-3 753.1 6.2 88.5 
a Values for CXCL8 and CCL5 were previously reported in (30) and are shown here for comparison. 
b NOI - No observable interaction. 
c NPA - No possible analysis due to insufficient signal. 
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Figure 7: 
 
 ka (M-1 s-1)  kd (s-1)  KD (nM) Chi2  
Link_TSG6 3.7 x 104 8.1 x 10-4 21.8 4.79 
 
  
  
200 400 600 800
-50
0
50
100
150
Time (s)R
el
at
iv
e 
re
sp
on
se
 (R
U
)
 TSG-6 Inhibits Chemokine:Glycosaminoglycan Interactions   28 
Figure 8: 
 
 
  
- L
ink
_T
SG
6
+ L
ink
_T
SG
6
0
50
100
**
Pe
rc
en
ta
ge
 o
f c
he
m
ok
in
e 
al
on
e
- L
ink
_T
SG
6
+ L
ink
_T
SG
6
0
50
100
*
Pe
rc
en
ta
ge
 o
f c
he
m
ok
in
e 
al
on
e
- L
ink
_T
SG
6
+ L
ink
_T
SG
6
0
50
100
**
Pe
rc
en
ta
ge
 o
f c
he
m
ok
in
e 
al
on
e
- L
ink
_T
SG
6
+ L
ink
_T
SG
6
0
50
100
**
Pe
rc
en
ta
ge
 o
f c
he
m
ok
in
e 
al
on
e
- L
ink
_T
SG
6
+ L
ink
_T
SG
6
0
50
100
**
Pe
rc
en
ta
ge
 o
f c
he
m
ok
in
e 
al
on
e
- L
ink
_T
SG
6
+ L
ink
_T
SG
6
0
50
100 **
Pe
rc
en
ta
ge
 o
f c
he
m
ok
in
e 
al
on
e
A B C
D E FCXCL12
CCL2
CCL5
CCL7 CCL21
CXCL4
 TSG-6 Inhibits Chemokine:Glycosaminoglycan Interactions   29 
 
Figure 9: 
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